Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1995 Aug;39(8):1756–1763. doi: 10.1128/aac.39.8.1756

Inhibition of recombinant Pneumocystis carinii dihydropteroate synthetase by sulfa drugs.

Y L Hong 1, P A Hossler 1, D H Calhoun 1, S R Meshnick 1
PMCID: PMC162822  PMID: 7486915

Abstract

Forty-four sulfa drugs were screened against crude preparations of recombinant Pneumocystis carinii dihydropteroate synthetase. The apparent Michaelis-Menten constants (Km) for p-aminobenzoic acid and 7,8-dihydro-6-hydroxymethylpterin pyrophosphate were 0.34 +/- 0.02 and 2.50 +/- 0.71 microM, respectively. Several sulfa drugs, including sulfathiazole, sulfachlorpyridazine, sulfamethoxypyridazine, and sulfathiourea, inhibited dihydropteroate synthetase approximately as well as sulfamethoxazole, as determined by the concentrations which cause 50% inhibition and/or by Ki. For all sulfones and sulfonamides tested, unsubstituted p-amino groups were necessary for activity, and sulfonamides containing an N1-heterocyclic substituent were found to be the most effective inhibitors. Folate biosynthesis in isolated intact P. carinii was approximately equally sensitive to inhibition by sulfamethoxazole, sulfachlorpyridazine, sulfamethoxypyridazine, sulfisoxazole, and sulfathiazole. Two of these drugs, sulfamethoxypyridazine and sulfisoxazole, are known to be less toxic than sulfamethoxazole and should be further evaluated for the treatment of P. carinii pneumonia.

Full Text

The Full Text of this article is available as a PDF (314.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ball P. Toxicity of sulphonamide-diaminopyrimidine combinations: implications for future use. J Antimicrob Chemother. 1986 Jun;17(6):694–696. doi: 10.1093/jac/17.6.694. [DOI] [PubMed] [Google Scholar]
  2. Björkman A., Phillips-Howard P. A. Adverse reactions to sulfa drugs: implications for malaria chemotherapy. Bull World Health Organ. 1991;69(3):297–304. [PMC free article] [PubMed] [Google Scholar]
  3. Bradford M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976 May 7;72:248–254. doi: 10.1006/abio.1976.9999. [DOI] [PubMed] [Google Scholar]
  4. Chen F., Cushion M. T. Use of an ATP bioluminescent assay to evaluate viability of Pneumocystis carinii from rats. J Clin Microbiol. 1994 Nov;32(11):2791–2800. doi: 10.1128/jcm.32.11.2791-2800.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Hughes W. T., Smith B. L. Efficacy of diaminodiphenylsulfone and other drugs in murine Pneumocystis carinii pneumonitis. Antimicrob Agents Chemother. 1984 Oct;26(4):436–440. doi: 10.1128/aac.26.4.436. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Hughes W. T., Smith B. L., Jacobus D. P. Successful treatment and prevention of murine Pneumocystis carinii pneumonitis with 4,4'-sulfonylbisformanilide. Antimicrob Agents Chemother. 1986 Mar;29(3):509–510. doi: 10.1128/aac.29.3.509. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Ittarat I., Asawamahasakda W., Bartlett M. S., Smith J. W., Meshnick S. R. Effects of atovaquone and other inhibitors on Pneumocystis carinii dihydroorotate dehydrogenase. Antimicrob Agents Chemother. 1995 Feb;39(2):325–328. doi: 10.1128/aac.39.2.325. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Merali S., Zhang Y., Sloan D., Meshnick S. Inhibition of Pneumocystis carinii dihydropteroate synthetase by sulfa drugs. Antimicrob Agents Chemother. 1990 Jun;34(6):1075–1078. doi: 10.1128/aac.34.6.1075. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Shiota T., Baugh C. M., Jackson R., Dillard R. The enzymatic synthesis of hydroxymethyldihydropteridine pyrophosphate and dihydrofolate. Biochemistry. 1969 Dec;8(12):5022–5028. doi: 10.1021/bi00840a052. [DOI] [PubMed] [Google Scholar]
  10. Sloand E., Laughon B., Armstrong M., Bartlett M. S., Blumenfeld W., Cushion M., Kalica A., Kovacs J. A., Martin W., Pitt E. The challenge of Pneumocystis carinii culture. J Eukaryot Microbiol. 1993 Mar-Apr;40(2):188–195. doi: 10.1111/j.1550-7408.1993.tb04902.x. [DOI] [PubMed] [Google Scholar]
  11. Thijssen H. H. A simplified radioassay method of dihydropteroate synthetase activity in Escherichia coli and its application for an inhibition study of p-aminobenzoi acid derivatives. Anal Biochem. 1973 Jun;53(2):579–585. doi: 10.1016/0003-2697(73)90109-7. [DOI] [PubMed] [Google Scholar]
  12. Volpe F., Ballantine S. P., Delves C. J. The multifunctional folic acid synthesis fas gene of Pneumocystis carinii encodes dihydroneopterin aldolase, hydroxymethyldihydropterin pyrophosphokinase and dihydropteroate synthase. Eur J Biochem. 1993 Sep 1;216(2):449–458. doi: 10.1111/j.1432-1033.1993.tb18163.x. [DOI] [PubMed] [Google Scholar]
  13. Volpe F., Dyer M., Scaife J. G., Darby G., Stammers D. K., Delves C. J. The multifunctional folic acid synthesis fas gene of Pneumocystis carinii appears to encode dihydropteroate synthase and hydroxymethyldihydropterin pyrophosphokinase. Gene. 1992 Mar 15;112(2):213–218. doi: 10.1016/0378-1119(92)90378-3. [DOI] [PubMed] [Google Scholar]
  14. Wall P. G., Porter K., Noone A., Goldberg D. J. Changing incidence of Pneumocystis carinii pneumonia as initial AIDS defining disease in the United Kingdom. AIDS. 1993 Nov;7(11):1523–1525. doi: 10.1097/00002030-199311000-00018. [DOI] [PubMed] [Google Scholar]
  15. Walzer P. D., Kim C. K., Foy J. M., Linke M. J., Cushion M. T. Inhibitors of folic acid synthesis in the treatment of experimental Pneumocystis carinii pneumonia. Antimicrob Agents Chemother. 1988 Jan;32(1):96–103. doi: 10.1128/aac.32.1.96. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Walzer P. D. Overview of animal models of Pneumocystis carinii pneumonia. J Protozool. 1991 Nov-Dec;38(6):122S–123S. [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES